|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00295100|
Recruitment Status : Completed
First Posted : February 22, 2006
Last Update Posted : June 21, 2007
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Tamoxifen||Phase 2|
The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial.
The study outcomes will be biological markers, rather than cancer incidence or mortality. Eligible study subjects will be women, between the ages 25-45, whose calculated lifetime breast cancer risk is > 20% (25% by the Couch model).
Study participants will be randomly assigned to receive either tamoxifen or placebo for one year. Participants will subsequently be followed for one year off of medication.
The primary objective is to evaluate the effectiveness of tamoxifen in reducing breast density by mammogram. Mammographic density has been correlated with breast cancer risk and reduced breast density may have the added benefit of improving the sensitivity of breast cancer screening in young women. Breast density will be employed as a marker of progression-related - proliferative - mechanisms of carcinogenesis.
Secondary study outcomes will include estrogen ratios (catechol estrogen/estradiol), and markers of oxidative DNA damage in peripheral blood and urine (markers of progression-related – mutational - events in carcinogenesis). The responsiveness of these outcomes will suggest the mechanisms through which tamoxifen exerts its preventive effect. Persistence of the markers after one year of treatment may also provide early information about the anticipated duration of the tamoxifen effect.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||78 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Cancer Risk and Biomarkers of Tamoxifen Chemoprevention|
|Study Start Date :||September 2000|
|Study Completion Date :||July 2006|
- Breast Density
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00295100
|United States, California|
|UCLA Medical Center|
|Los Angeles, California, United States, 90095|
|United States, Massachusetts|
|Dana Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|United States, Michigan|
|Wayne State University|
|Detroit, Michigan, United States, 48201|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, Pennsylvania|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Fox Chase Cancer Center|
|Philadelphia, Pennsylvania, United States, 19111|
|European Institute of Oncology|
|Principal Investigator:||Susan Domchek, MD||University of Pennsylvania|